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Abstract 29 
The Notch pathway has been reported to control tissue damage in acute kidney diseases. To 30 
investigate potential beneficial nephroprotective effects of targeting Notch, we developed 31 
chemically functionalized γ-secretase inhibitors (GSIs) targeting γ-glutamyltranspeptidase (γ-32 
GT) and/or γ-glutamylcyclotransfase (γ-GCT), two enzymes overexpressed in the injured 33 
kidney, and evaluated them in in vivo murine models of acute tubular and glomerular damage. 34 
Exposure of the animals to disease-inducing drugs together with the functionalized GSIs 35 
improved proteinuria and, to some extent, kidney dysfunction. The expression of genes 36 
involved in the Notch pathway, acute inflammatory stress responses and the renin-angiotensin 37 
system was enhanced in injured kidneys, which could be downregulated upon administration 38 
of functionalized GSIs. Immunohistochemistry staining and western blots demonstrated 39 
enhanced activation of Notch1 as detected by its cleaved active intracellular domain during 40 
acute kidney injury, and this was down-regulated by concomitant treatment with the 41 
functionalized GSIs. Thus, targeted γ-secretase-based prodrugs developed as substrates for γ-42 
GT/γ-GCT have the potential to selectively control Notch activation in kidney diseases with 43 
subsequent regulation of the inflammatory stress response and the renin-angiotensin 44 
pathways.   45 
 46 
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Introduction  51 
Recent advanced knowledge on acute and chronic renal injury has yielded several common 52 
candidate pathways for designing targeted therapeutics, which include the Notch pathway, the 53 
oxidative stress response and the renin-angiotensin system (RAS) (3,20,21,31,42). The Notch 54 
pathway is a target for therapeutic intervention, not only in kidney diseases but also in several 55 
other disorders (20,36). Notch is a membrane inserted protein with its active part directed 56 
toward the intracellular space and which needs hydrolysis by the γ-secretase complex to 57 
become active (20). The enzyme γ-secretase is a large protease complex composed of a 58 
catalytic aspartyl protease subunit (presenilin-1 or -2) and three support subunits (presenilin 59 
enhancer protein (pen)-2, aph-1 and nicastrin), all being membrane-inserted proteins. The γ-60 
secretase complex activates Notch by hydrolyzing a peptide bond of the Notch protein at an 61 
intra-membrane site, allowing cleaved Notch, also referred to as Notch intracellular domain 62 
(NICD), to migrate to the nucleus where it activates responsive genes (45). The intra-63 
membrane activity of the γ-secretase has also been involved in the release from the membrane 64 
of other biologically relevant membrane proteins involved in physiological and pathological 65 
processes, including amyloid precursor protein, LDL-receptors, insulin-like growth factor or 66 
CD44. Therefore, in order to develop selective therapies for kidney diseases involving the 67 
control of Notch activation, it is desired to achieve only localized γ-secretase inhibition, thus 68 
protecting the other functions of this enzyme and of the Notch pathway in non-target organs. 69 
 70 
Toward this goal and based on our previous knowledge that the activities of the peptidases γ-71 
glutamyltranspeptidase (γ-GT) and aminopeptidase A (APA) are increased in various 72 
compartments of injured kidneys in rodent experimental models as well as in human samples, 73 
we have designed, synthesized and evaluated targeted γ-secretase inhibitors (GSIs) as prodrug 74 
substrates for theses enzymes (17). Preliminary in vivo results suggested the possibility of the 75 
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approach of using targeted GSIs in an experimental model of acute kidney injury. However, 76 
in our previous report, the biological consequences of exposing the animals to these targeted 77 
compounds and the in vivo effects on the expression of the components of the Notch pathway 78 
and other associated cellular responses were not studied. Thus in the present report, these 79 
functionalized γ-secretase-based prodrugs were evaluated in the experimental murine model 80 
of severe acute tubulointerstitial injury induced by aristolochic acid (AA) and the more 81 
progressive model of glomerular damage after exposure to adriamycin (ADR). Control and 82 
treated animals were monitored throughout the experiments for weight, proteinuria and 83 
relevant serum chemistry values. The toxicological profile of the N-acetyl-γ-Glu-γ-secretase-84 
inhibitor (N-Ac-γ-Glu-GSI) prodrug and its metabolite amine-GSI was determined in the 85 
plasma. To investigate the potential biological consequences of exposing the animals to these 86 
various compounds, we used real-time quantitative PCRs performed on mRNA extracted 87 
from the kidneys of the experimental animals as well as immunohistology and western 88 
blotting. The results demonstrated an activation of Notch1 with upregulation of the expression 89 
of genes involved in the Notch pathway, inflammatory stress response and the RAS, which 90 
could be selectively down-regulated upon administration to the mice of the N-Ac-γ-Glu-GSI 91 
and/or its active metabolite amine-GSI, together with selective inhibition of Notch cleavage. 92 
93 
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Materials and Methods 94 
Animal models of induced kidney injury  95 
All experiments were conducted in accordance with federal and local regulations, according 96 
to a protocol approved by the animal ethics committee of the Canton de Vaud, Switzerland 97 
(permit No 2655.0). Kidney injury was induced by intraperitoneal (i.p.) injection of 98 
aristolochic acid (AA, Sigma-Aldrich, Buchs, Switzerland, 1x5 mg/kg) or of adriamycin 99 
(Adriblastin, Pfizer, Zürich, Switzerland, 1x10 mg/kg) in 10 weeks old BALB/c male mice 100 
(n=5-7 mice/experimental group). The γ-secretase inhibitors (GSIs) compounds were diluted 101 
in 0.9% NaCl and administered i.p., starting one day before the disease-inducing drugs (day -102 
1) at a dose of 10 mg/kg for amine-GSI or 30 mg/kg for N-Ac-γ-Glu-GSI, and then twice 103 
daily until day 6 evening. A control group received the GSIs prodrugs without induction of 104 
kidney injury. The animals were weighted at days 0, 3 and 6, and sacrificed at day 7 morning. 105 
Proteinuria was assessed semi-quantitatively using Albustix reagent strips (Bayer, Basel, 106 
Switzerland). At the end of the treatment period, the mice were sacrificed, and the liver and 107 
both kidneys were removed. The kidneys were spliced in four equal fragments containing 108 
equivalent amounts of cortex and medulla. One fragment was snap-frozen in liquid nitrogen 109 
for qRT-PCR and western blot experiments, one fragment was included in OCT (Tissue-Tek, 110 
VWR International, Dietikon, Switzerland) and frozen for histoenzymography and 111 
immunohistochemistry experiments, one fragment was frozen at -80°C and was used to 112 
quantify drugs, and one fragment was fixed in 4% paraformaldehyde and included in paraffin 113 
for histology. Hematoxylin/eosin (HE) and Masson’s trichrome blue (MTB) stainings of 114 
paraffin-embedded mouse kidney sections were performed using standard routine procedures. 115 
Blood samples were collected in tubes containing EDTA, plasma was separated by 116 
centrifugation and stored at -80°C. The clinical blood chemistry evaluation (kidney and liver 117 
function tests) in mouse plasma was performed according to standard procedures. 118 
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Immunohistochemistry  119 
OCT-embedded frozen kidneys were cut at 7 μm. The sections were air-dried, fixed for 10 120 
min in cold (-20 °C) methanol, rinsed in PBS 0.1% Triton X-100 (PBS/Triton), and blocked 121 
for 30 min with PBS/Triton containing 5% bovine serum albumin (BSA). Endogenous 122 
peroxidase and biotin were blocked using 3% H2O2 and avidin/biotin blocking kit (Vector 123 
Laboratories, Burlingame, CA 94010, USA), respectively. The rabbit anti-Notch1 antibody 124 
(clone D1E11, Cell Signaling Technology, Leiden, The Netherland; diluted 1/50 in PBS/5% 125 
BSA) or the rabbit anti-cleaved Notch1 antibody (clone Val1744, Cell Signaling; diluted 1/50 126 
in PBS/5% BSA) were added to the sections for 1 h. The slides were rinsed with PBS/Triton 127 
three times, incubated for 1 h with biotinylated anti-rabbit secondary antibody (Vector 128 
Laboratories, diluted 1/500 in PBS/5% BSA), washed with PBS, incubated with 129 
streptavidin/horse radish peroxidase (HRP) (Dako, Bollschweil, Germany; diluted 1/500) for 130 
1 h, followed by 15 min with 3,3′diaminobenzidine (DAB, Dako). The slides were washed in 131 
distilled water, mounted in Aquamount, (Immu-mount, Thermo Shandon Pittsburgh, PA, 132 
USA) and analyzed.  133 
For the staining of α-smooth muscle actin (α-SMA), paraffin-embedded kidney sections were 134 
used. Slides were deparaffined following standard procedures and endogenous peroxidase was 135 
blocked using 1% H2O2 in methanol. Slides were then rehydrated by washing in decreasing 136 
gradients of ethanol (100% twice, 95% twice, 80% once) followed by tap water, then blocked 137 
10 min in PBS/10% goat serum before adding the primary antibody for 1 h (rabbit anti-α-138 
SMA, Abcam; diluted 1/200 in PBS-0.1% BSA), followed by anti-rabbit HRP and DAB. The 139 
slides were rinsed in tap water and briefly counterstained with Harris hematoxyline. For NFkB 140 
p65, the same protocol was applied with an added antigen retrieval step using citrate buffer 141 
pH 6 and heating in microwave, before adding the primary antibody (rabbit anti-NFkB p65, 142 
GeneTex; diluted 1/1000 in PBS/0,1% BSA).   143 
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 Real-time quantitative PCR (qRT-PCR)  144 
Total RNA was extracted from frozen kidney fragments of either untreated mice or mice 145 
treated with the various drugs (n=5-7 mice per experimental group), using the TRIzol reagent 146 
(Life Technologies, USA) as per the manufacturer’s instructions. Briefly, 10mg of kidney 147 
sample was homogenized using a polytron (VWR International). The nucleic acids were 148 
purified by chloroform/isopropanol extraction, quantified with the NanoDrop-ND2000 149 
(Thermo Scientific, USA) and treated by DNase (Promega, USA). DNase-treated RNA 150 
samples (260/280 nm absorbance ratio of 1.9-2.0) were subjected to cDNA synthesis with the 151 
iScript
TM
 cDNA Synthesis Reverse Transcription (RT) kit (Bio-rad Laboratories, USA) as per 152 
the manufacturer’s instructions. For gene expression profiling, SYBR Green (SensiMixTM 153 
SYBR kit, Quantace)-based qPCRs were performed for quantification of a particular 154 
transcript using specific primers with Rotor-Gene 6000 instrument (Corbett Research, 155 
Australia). Intron spanning and exon-specific primers were designed and synthesized by 156 
Microsynth, Switzerland. The sequences of the primers used are provided in Table 1. 157 
Standard curve analysis (>80% efficiency with single melting curve) was performed to 158 
validate the primers and PCR amplicons checked on ethidium bromide-containing agarose 159 
gels. To calculate the relative changes in mRNA expression, the ddCt method (25) was used. 160 
Gene expression levels were normalized to Gapdh and the control (vehicle-treated) animal 161 
group was assigned 100%. The levels of expression of interleukin (IL)-1β, IL-6, nuclear 162 
factor-kappa (NFk)B1 and NFkB2, Notch1, hairy and enhancer of split-1 (Hes1), Nephrin1, 163 
Snail, cyclin-dependent kinase (CDK)2, angiotensinogen (AGT), renin, APA and angiotensin 164 
receptor 1 (AT1) mRNAs were quantified by qRT-PCR and averaged for all animals.  165 
 166 
Western blots  167 
8 
 
Frozen mice kidneys were homogenized using a polytron in RIPA lysis buffer (150mM 168 
sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50mM Tris, pH 8.0, 169 
complete-EDTA free protease inhibitor cocktail (Roche, Germany)) and centrifuged for 20 170 
min (13000g) at 4°C. Tissue lysates were separated by SDS-PAGE and proteins transferred to 171 
PVDF membrane (Bio-Rad, USA). Following transfer, the membranes were probed with 172 
rabbit anti-cleaved Notch1 antibody (clone Val1744; diluted 1:1000) overnight at 4°C. After 173 
washing, blots were incubated for 1 h with a secondary anti-rabbit HRP antibody (dilution 174 
1:1000, Cell Signaling Technology) at room temperature. Blots were probed with an anti-175 
GAPDH antibody (clone 14C10, Cell Signaling Technology; diluted 1:1000) as a loading 176 
control. Membranes were developed using Pierce ECL Plus (Thermo Scientific, USA). Bands 177 
intensities were quantified using Image J and presented as relative expression to the loading 178 
control (GAPDH). 179 
 180 
Statistical analysis  181 
The level of statistical significance between multiple experimental groups was assessed using 182 
one-way analysis of variance (ANOVA) along with Tukey’s post-test for multiple 183 
comparisons (GraphPad Prism version 6, California). P values<0.05 were considered 184 
significant (*p<0.05, **p<0.01, ***p <0.001).  185 
9 
 
Results 186 
Effects of the functionalized GSIs in the aristolochic acid-induced murine model of acute 187 
tubulointerstitial injury 188 
The chemical structures of the compounds used here are shown in Figure 1. Previous in vitro 189 
and ex vivo experiments (17) had demonstrated the cleavage of the inactive prodrug N-Ac-γ-190 
Glu-GSI resulting in the release of the active amine-GSI in the presence of the enzymes γ-191 
GT/γ-GCT, while no further hydrolysis to the free inhibitor occurred. Pharmacokinetic 192 
experiments, measuring the distribution of the N-Ac-γ-Glu-GSI prodrug and its metabolite 193 
amine-GSI following i.p. administration in mice, had determined the optimal dose and mode 194 
of administration for these compounds (17). Using a preliminary in vivo setting, we could also 195 
demonstrate that the potent γ-secretase inhibitor amine-GSI was selectively liberated from the 196 
prodrug N-Ac-γ-Glu-GSI in injured kidneys (17). Thus, the N-Ac-γ-Glu-GSI prodrug and its 197 
amine-GSI metabolite were chosen to test selective kidney protection in the experiments 198 
described hereafter. To further investigate for potential beneficial nephroprotective effects of 199 
the compounds, firstly, the aristolochic acid (AA)-induced in vivo murine model of acute 200 
tubulointerstitial renal damage was selected. The efficacy and toxicity profile of the N-Ac-γ-201 
Glu-GSI prodrug and its metabolite amine-GSI in control and diseased animals was analyzed 202 
using standard clinical chemistry markers at day 7 after administration in our in vivo model 203 
(Table 2). The results showed that control mice treated with the N-Ac-γ-Glu-GSI prodrug 204 
alone experienced no obvious toxicity other than a slight increase in liver enzymes values 205 
(mainly alanine aminotransferase, ALAT and aspartate aminotransferase, ASAT). AA 206 
treatment induced acute renal failure as evidenced by significant elevation of serum creatinine 207 
and urea levels. The addition of the N-Ac-γ-Glu-GSI ameliorated kidney dysfuntion, but did 208 
not allow complete prevention of acute tubulopathy induced by AA. Interestingly, AA had a 209 
moderate hepatotoxic effect (mainly cytolysis) which was also limited by the adminisration of 210 
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the prodrug, possibly due to upregulation of γ-GT in acutely injured hepatocytes. 211 
Administration of the amine-GSI i.e. the N-Ac-γ-Glu-GSI prodrug metabolite directly yielded 212 
similar results. 213 
 214 
Mice exposed to AA alone or treated with either the N-Ac-γ-Glu-GSI or the metabolite 215 
amine-GSI were evaluated clinically (behavior, feeding) and their weight and level of 216 
proteinuria was measured at baseline (day 0), then at day 3 and 6 after administration of the 217 
various compounds (Figure 2). AA exposure induced severe weight loss, most probably due 218 
to decreased food and liquid intake (as determined by monitoring daily the food and drink 219 
stocks as well as cages beddings). While there was no significant beneficial effect of the GSIs 220 
analogs on weight loss during the 7 days follow-up, both drugs resulted in a remarkable 221 
improvement of proteinuria, already by day 3. Histological evaluation of the kidneys of the 222 
experimental mice confirmed the development of severe acute tubulointerstitial lesions after 223 
AA exposure (Figure 3A), which affected mainly the proximal tubules as previously 224 
described (2). The prodrug N-Ac-γ-Glu-GSI given alone had no obvious deleterious effects on 225 
the liver and kidney architectures. In our experimental setting, the N-Ac-γ-Glu-GSI treatment 226 
regimen could only partially prevent the severe tubulopathy induced by AA, corroborating the 227 
kidney function data. Despite the observed slight elevation of liver enzymes, the liver 228 
structure was mostly preserved in all experimental groups (Figure 3B). In our experimental 229 
model, mice were sacrificed on day 7, and besides the protective effect of the N-Ac-γ-Glu-230 
GSI prodrug on acute tubulointerstitial lesions, we also observed a decreased expression of α-231 
smooth muscle actin (α-SMA) at this early time-point, suggesting a protective effect on the 232 
development of a profibrotic response following acute injury.  233 
 234 
We next investigated specific local inhibition of the cleavage of Notch in the kidneys of 235 
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animals exposed to AA alone or in the presence of N-Ac-γ-Glu-GSI (Figure 4). 236 
Immunohistochemistry stainings (Figure 4A) showed that while exposure to AA induced 237 
Notch1 expression and Notch1 cleavage reflecting Notch activation, treatment with the 238 
functionalized N-Ac-γ-Glu-GSI significantly prevented the expression of cleaved Notch1. By 239 
itself and in the absence of AA-mediated injury, N-Ac-γ-Glu-GSI had no effect on the 240 
cleavage of Notch in the kidney. These results were futher confirmed by western blot analysis 241 
of cleaved Notch1 (also referred to as NICD) expression levels in control, AA-diseased and 242 
AA-diseased-N-Ac-γ-Glu-GSI-treated kidney samples (Figure 4B). Finally, using 243 
histoenzymography, we further evaluated the effects of AA and the N-Ac-γ-Glu-GSI on the 244 
activity of the target enzyme, γ-GT. At day 7 after AA exposure, kidneys of diseased mice 245 
were severely damaged so that we could not analyze any γ-GT activity at this late time-point 246 
nor illustrate, directly on tissue sections, the specific local activation of the GSI prodrug as 247 
substrate for this enzyme. However, in previous ex-vivo experiments, we were able to 248 
demonstrate early upregulation of the enzyme γ-GT mainly in proximal tubules of diseased 249 
kidneys and targeted activation of our prodrug allowing local inhibition of the hydrolytic 250 
cleavage of Notch (17). Overall, these data highlighted the protective effects but also the 251 
limitation of functionalized GSIs analogs, when used alone, in preventing severe acute 252 
tubulointerstitial injury such as in our in vivo model.  253 
 254 
Evaluation of downstream pathways associated with the inhibition of Notch1 cleavage 255 
At the end of the treatments (day 7), the animals were sacrificed and kidney sections were 256 
stored snap frozen for the determination by qRT-PCR of the mRNA levels of Notch1-257 
responsive genes (Figure 5A, Notch1, Nephrin1, HES1, Snail and CDK2) and Notch1-258 
inducible inflammatory genes (Figure 5B, IL-1β, IL-6, NFκB1 and NFκB2). By itself, the N-259 
Ac-γ-Glu-GSI did not induce the expression of genes of the Notch-dependent pathways. 260 
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Interestingly, compared to control animals, in animals exposed to AA, a significant induction 261 
of genes of the Notch downstream signaling pathway (Notch1, Nephrin1, HES1, Snail, 262 
CDK2) and of pro-inflammatory cytokines (IL-1β and IL-6) was observed, as well as an 263 
increased expression of genes encoding the transcription factors NFκB1and NFκB2; all of 264 
which could be significantly reduced by concurrent treatment with N-Ac-γ-Glu-GSI. 265 
Comparable information was obtained when analyzing kidneys of mice administered AA and 266 
the amine-GSI (data not shown). To further confirm these gene expression data on Notch-267 
responsive genes and related inflammatory pathways, we investigated the expression of NFkB 268 
at the protein level; NFkB being one of the main regulators of cellular stress and inflammatory 269 
responses. As shown by immunohistochemistry on kidney sections (Figure 5C), while there 270 
was a high expression of NFkB p65 (active subunit of the NFkB transcription complex) in AA-271 
injured kidneys, this expression was limited if the mice had also received the N-Ac-γ-Glu-GSI 272 
treatment. 273 
 274 
As dysfunction of the RAS has been involved in the development and/or progression of 275 
inflammatory disorders of the kidney, we also determined by qRT-PCR if modulation of the 276 
Notch pathway by GSIs, either the N-Ac-γ-Glu-GSI or the amine-GSI, may also induce 277 
kidney-specific modifications in the expression of components of the RAS (Figure 6). In the 278 
RAS, the enzymes renin and angiotensin converting enzyme (ACE) sequentially hydrolyze 279 
the substrate angiotensinogen (AGT) to release the active octapeptide angiotensin (Ang) II 280 
able to bind to two functional receptors, AT1, which is the main receptor in the kidney, and 281 
AT2. Then the enzyme APA can hydrolyze the N-terminal Asp of Ang II, releasing Ang III, 282 
with different functions than Ang II. Thus, as APA is the main peptidase initiating the 283 
degradation of Ang II, we also evaluated this gene. Following AA administration to the mice, 284 
up-regulation of all the mRNAs evaluated for the RAS was observed, including the 285 
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expression of APA mRNA, suggesting a feed-back mechanism. However, the induction of 286 
AT1 gene was low, and not always consistent between the experiments. Overall, these 287 
experiments demonstrated that the functionalized GSI prodrug was able to control, in part, the 288 
tissue stress response in vivo after severe acute kidney tubular injury by controlling the 289 
activation of the Notch pathway and its responsive genes downstream.  290 
 291 
Effects of the functionalized GSIs in the adriamycin-induced murine model of glomerular 292 
injury 293 
The effect of the functionalized GSIs was also determined in another experimental model of 294 
renal disease induced by the administration of adriamycin (ADR). As opposed to AA which 295 
mainly induces acute tubulopathy, ADR administration is followed by progressive podocyte 296 
injury leading to glomerulosclerosis. Using human and mouse samples of diseased kidneys, 297 
we have previously shown that the enzyme γ-GT is preferentially expressed in the proximal 298 
tubules of injured kidneys and only marginally in the glomerulus (17). Therefore, in the ADR 299 
model, we used the already active amine-GSI metabolite which is not dependant on γ-GT 300 
enzymatic activation within the target organ. In the ADR experimental model as in the AA 301 
model, concomitant treatment with the amine-GSI metabolite was able to control proteinuria, 302 
but not weight loss (Figure 7A). ADR administration also induced Notch1 expression and 303 
genes of the RAS in the injured kidneys, which could to some extent be down-regulated by 304 
concomitant administration of the amine-GSI (Figure 7B). As compared to the AA model of 305 
severe tubulopathy, acute inflammatory pathway genes were not all consistently upregulated 306 
in this setting, which corresponded to a less acutely toxic and destructive effect of ADR on 307 
renal tissues; ADR mainly inducing progressive glomerular damage. Figure 7C indeed shows 308 
that ADR-mediated lesions are discrete on normal histology (light microscopy HE staining) at 309 
an early time-point, as ADR affects the glomerulus with no acute tubulointerstitial injury. 310 
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There is however a certain degree of glomerulosclerosis (fibrotic lesions are stained in blue in 311 
MTB sections, Figure 7C lower panels) in the absence of amine-GSI treatment. Finally, 312 
western blot analysis of kidney samples confirmed the modulation of Notch1 activation (as 313 
detected by its active cleaved form) upon administration of amine-GSI to ADR-treated mice 314 
(Figure 7D). 315 
316 
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Discussion  317 
Within the kidney, injury to tubular or glomerular cells is the initiating cause of acute and 318 
chronic diseases, leading to progressive dysfunction and end-stage renal failure. Inflammatory 319 
and non-inflammatory stresses affect the tubulointerstitial tissue and/or the glomerulus and 320 
lead to alterations in their structure, permeability and function. However, irrespective to the 321 
initial insult, disease progression ultimately leads to irreversible glomerulosclerosis, 322 
interstitial fibrosis and tubular atrophy. Recent studies of various renal diseases in humans 323 
and rodent experimental models have yielded several candidate pathways for therapy, which 324 
include the Notch pathway (3,6,7,14,22,30,31,40,43,47).
 
In experimental mouse models, 325 
conditional overexpression of the active Notch1 protein in podocytes results in massive 326 
proteinuria and glomerulosclerosis, leading to renal failure and death of the animals. Genetic 327 
deletion of Notch transcriptional binding partners or treatment with γ-secretase inhibitors, 328 
preventing Notch activation and translocation to the nucleus, protected the animals from 329 
nephrotic syndrome. Thus, current data strongly suggest that targeted pharmacologic 330 
inhibition of the Notch signaling pathway may prevent kidney damage and improve organ 331 
survival.  332 
 333 
Notch1-4 are transmembrane proteins that interact with ligands of the Jagged and Delta 334 
family. This interaction triggers a series of proteolytic cleavages within the cell. The final γ-335 
secretase complex-mediated cleavage releases the NICD, which is a transcription factor. The 336 
function of Notch is context-dependent, regulating tissue homeostasis, cell differentiation and 337 
stem cell maintenance in adult life. Regulation of Notch pathway signaling mainly occurs at 338 
the levels of ligand binding and γ-secretase complex-mediated cleavage (20). We have 339 
previously shown that an N-Ac-γ-Glu-GSI prodrug was selectively metabolized in the kidney 340 
after i.p. application to an amine-GSI metabolite displaying high Notch antagonism (17). Thus 341 
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in the present study, the potential beneficial nephroprotective effects of targeting Notch with 342 
these functionalized GSI-based prodrugs were investigated using two in vivo murine models. 343 
AA is a natural herbal component which is toxic to the renal tubular epithelial cells, leading to 344 
a dose-dependent rapidly progressive interstitial nephropathy and renal failure (5). AA acute 345 
tubular toxicity is a result of mitochondrial injury with defective activation of antioxidative 346 
enzymes leading to impaired regeneration, apoptosis and defective autophagy of proximal 347 
tubular epithelial cells, thus progressive tubular atrophy and interstitial fibrosis (37,50). ADR 348 
is an anticancer chemotherapeutic agent widely used in the clinic. ADR-induced nephropathy 349 
(10,23,29,32) is a well described rodent model of progressive glomerular disease, mediated by 350 
an oxidative stress and characterized by massive proteinuria due to podocyte injury, followed 351 
by glomerulosclerosis, tubulo-interstitial inflammation and fibrosis. ADR-induced renal 352 
injury has been shown in numerous studies to be modulated both by non-immune and immune 353 
factors. In the present study, we show that treatment with functionalized GSIs could alleviate 354 
proteinuria and slightly limit acute kidney dysfunction of mice exposed to AA or ADR. Gene 355 
expression profiles analysis of kidney sections demonstrated the induction of Notch1 and its 356 
downstream signalling, as well as a very high expression of the active cleaved form of Notch1 357 
by immunohistochemistry and western blot analysis of injured kidneys, which was reduced by 358 
concomitant treatment with the functionalized GSIs. However, although the administration of 359 
these GSIs could inhibit the activation of Notch and its downstream pathways, selectively 360 
blocking Notch activation in the kidney proved insufficient to prevent acute renal failure due 361 
to severe tubulointerstitial or glomerular injury, such as induced in our models.  362 
 363 
Following Notch activation mediated by the transmembrane γ-secretase complex, the released 364 
NICD translocates to the nucleus where it interacts with transcription factors and histone 365 
acyltransferases (8,35,46). Nuclear localization of the NICD promotes the transcription of 366 
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Notch-dependent target genes in a context- and cell-dependent manner. Several studies 367 
conducted to identify genes regulated by Notch have demonstrated that these responsive 368 
genes include Notch itself, HES1, Snail, Nephrin, CDK2 and genes involved in pro-369 
inflammatory pathways (13,18,24,26,34,38,39,41,49). In mice, a loss of the slit diaphragm 370 
protein Nephrin was observed exclusively in podocytes expressing activated Notch. 371 
Overexpression of activated Notch decreased cell surface Nephrin and increased cytoplasmic 372 
Nephrin in transfected HEK 293 cells. Thus, Notch signaling induces endocytosis of Nephrin, 373 
thereby triggering the onset of proteinuria (44). Notch signaling has been shown to be 374 
associated with inflammatory diseases (1,11,14). The pro-inflammatory cytokine IL-6 has 375 
also been shown to be regulated by Notch signaling and controlled by p53 and the NFκB 376 
pathway (11,15). A complex signaling crosstalk has also been described in cardiovascular 377 
diseases where inflammatory responses regulate Notch signaling and reciprocally Notch has a 378 
functional role on inflammatory processes (36). Overall, Notch signaling has a role in 379 
controlling the cell cycle via CDK2, cell differentiation and transcription via HES1, cell 380 
adhesion and epithelial-to-mesemchymal transdifferentiation (EMT) via Snail and Nephrin, as 381 
well as the immune response via the cytokines IL-1β, IL-6 and the NFκB pathway. In the 382 
present report, quantitative real-time PCRs performed on mRNAs extracted from the acutely 383 
injured kidneys demonstrated an upregulation of the expression of down-stream genes of the 384 
Notch pathway, including Notch1, HES1, Snail and CDK2, and of IL-1β and IL-6 likely 385 
mediated by the NFκB pathway, which could all be selectively down-regulated upon 386 
administration to the AA and ADR-exposed animals of the functionalized GSIs. 387 
 388 
The renin-angiotensin system (RAS) is a main contributor in the regulation of kidney function 389 
in homeostatic and disease conditions, acting independently in the blood and the kidney 390 
(12,42). All the RAS components have been found in the kidney, differentially expressed in 391 
18 
 
various renal compartments. Conversion by APA, a membrane-bound zinc-dependent 392 
aminopeptidase expressed in renal proximal tubules and in glomerular cells and which is 393 
upregulated upon tissue injury (17), of Ang II to Ang III was shown to be critical for 394 
angiotensin-mediated effects in the kidney (19,27,28,33). The AT1 and AT2 receptors display 395 
opposing functions and selectivity for Ang II and Ang III (4,33). In the intact kidney the Ang 396 
II/AT1R axis is the more highly expressed, whereas in diseased conditions the Ang III/AT2R 397 
axis may represent a physiological response to renal tissue stress. Previous data suggest a 398 
crosstalk between Ang II and the activation of the Notch pathway in the development of renal 399 
diseases. Ang II was shown to induce the synthesis by murine podocytes of extracellular 400 
matrix components and transforming growth factor (TGF)-β1 that could be inhibited by GSIs 401 
(48). In isolated perfused rat kidneys and cultured human podocytes, Ang II down-regulated 402 
Nephrin expression via Notch1 activation and nuclear translocation of Snail. HES1 is a 403 
Notch1-downstream transcription factor that was shown to activate Snail in cultured 404 
podocytes. Changes of the Snail/Nephrin axis in patients with advanced diabetic nephropathy 405 
were normalized by pharmacological inhibition of the RAS. Overall, these data point to the 406 
relevant role of Ang II in promoting glomerular injury via activation of Notch1/Snail 407 
signaling in podocytes, resulting in the down-regulation of Nephrin expression, the integrity 408 
of which is crucial for the glomerular filtration barrier (9). Therefore, our observation in the 409 
present report of a link between targeted blockade of the Notch pathway, inflammatory stress 410 
responses and the RAS opens new therapeutic implications for the treatment of kidney 411 
diseases, suggesting that the addition of drugs able to control Notch activation such as 412 
functionalized GSIs may be of therapeutic value.  413 
 414 
 415 
 416 
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Ac: acetyl 418 
AA: aristolochic acid; 8-methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylic acid 419 
ADR: Adriamycin 420 
Ang: angiotensin 421 
APA: glutamyl aminopeptidase (EC 3.4.11.7.) 422 
AT1/2: angiotensin receptor type 1 or type 2 423 
γ-GT: γ-glutamyl-transpeptidase (EC 2.3.2.2.) 424 
RAS: renin-angiotensin system 425 
γ-GCT: γ-glutamylcyclotransferase  (EC 2.3.2.4.) 426 
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Tables 635 
 636 
Table 1. Sequences of the primers used for the qPCR experiments. 637 
gene symbol forward sequence (5'–3') reverse sequence (5'–3') 
AGT GGCAAATCTGAACAACATTGG TTCCTCCTCTCCTGCTTTGA 
APA TGGACTCCAAAGCTGATCCT TCAGCCCATCTGACTGGAAT 
AT1 ACTCACAGCAACCCTCCAAG CTCAGACACTGTTCAAAATGCAC 
CDK2 TTCCTCTTCCCCTCATCAAG ACGGTGAGAATGGCAGAAAG 
Gapdh GTCGGTGTGAACGGATTTG  AAGATGGTGATGGGCTTCC 
HES1 TGCCAGCTGATATAATGGAGAA CCATGATAGGCTTTGATGACTTT 
IL-1β GGGCCTCAAAGGAAAGAATC CTCTGCTTGTGAGGTGCTGA 
IL-6 AGAAGGGCCTGGAATGAAAC AAGACCCTGCTGGAACAAGA 
Nephrin1 GGATATAGTCTGCACCGTCGAT TCAGTTCCTCCTCGTCTTCC 
NFκB1 GGGTCTGGGGATACTGAACA GCCTCCATCAGCTCTTTGAT 
NFκB2 TGGAACAGCCCAAACAGC CACCTGGCAAACCTCCAT 
Notch1 CTGGACCCCATGGACATC AGGATGACTGCACACATTGC 
Renin GGAGGAAGTGTTCTCTGTCTACTACA GCTACCTCCTAGCACCACCTC 
Snail CTTGTGTCTGCACGACCTGT CAGGAGAATGGCTTCTCACC 
 638 
639 
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Table 2. Serum chemistry profile of mice exposed to aristolochic acid (AA) alone, or with 640 
the N-Ac-γ-Glu-GSI or the amine-GSI. 641 
 642 
  Creat 
 μmol/l 
Urea 
mmol/l 
Prot 
g/l 
Alb 
g/l 
ASAT 
U/l 
ALAT 
U/l 
AlkP 
U/l 
Control mean 
+ sd 
43.4    
4.8 
8.8 
1.1 
53.4 
3.2 
30.7 
2.5 
372.0 
77.6 
55.6 
4.2 
141.5 
11.5 
N-Ac-γ-Glu-GSI  37.4 
4.0 
 
7.7 
0.5 
54.0 
2.5 
30.8 
1.3 
516.0 
212.1 
92.4 
26.3 
 
136.1 
18.1 
AA  251.4 
69.0 
 
112.3 
15.6 
52.2 
4.7 
29.4 
3.0 
459.4 
204.6 
179.8 
73.8 
 
108.7 
27.8 
AA +                     
N-Ac-γ-Glu-GSI 
160.3 
69.3 
85.2 
20.5 
46.8 
15.1 
26.3 
8.1 
375.9 
120.4 
43.4 
16.8 
94.6 
25.6 
AA + 
amine-GSI 
 169.0 
29.3 
90.0 
9.8 
57.6 
2.4 
31.0 
2.8 
550.6 
219.6 
208.8 
83.5 
140.0 
20.3 
 643 
Abbreviations: Creat: creatinine; Prot: proteins; Alb: albumin; ASAT: aspartate aminotransferase; ALAT: 644 
alanine aminotransferase; AlkP: alkaline phosphatase. 645 
 646 
 647 
 648 
 649 
650 
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Figures Legends 651 
Figure 1. Chemical structure of the N-Ac-γ-Glu-GSI prodrug and its proteolytic activation.  652 
The prodrug is composed of the active compound (γ-secretase inhibitor, GSI), a linker 653 
(amine) and the targeting N-acetyl (N-Ac)-γ-Glu-moiety as substrate for the releasing acylase 654 
and γ-Glu-transpeptidase (γ-GT) and/or γ-Glu-cyclotransferase peptidases γ-GCT (arrows). 655 
 656 
Figure 2. Body weight (A) and proteinuria (B) of mice exposed to aristolochic acid, N-Ac-γ-657 
Glu-GSI, aristolochic acid together with N-Ac-γ-Glu-GSI and aristolochic acid with amine-658 
GSI. 659 
Acute tubular injury was induced in 10 weeks old BALB/c male mice by i.p. injection of 660 
aristolochic acid (AA). The GSI analogs were administered i.p., starting one day before 661 
injection of AA (day -1) and then twice daily until day 6 evening. The animals were 662 
monitored clinically daily, weighted and the level of albuminuria was semi-quantitatively 663 
assessed at day 0, day 3 and day 6. Results are presented as means + sd for all mice in each 664 
experimental group, with comparisons between treated versus control animals or between 665 
treatments. (**p<0.01; ***p<0.001; NS not statistically significant). 666 
 667 
Figure 3. Histology of the kidneys and livers of mice treated with aristolochic acid and the 668 
N-Ac-γ-Glu-GSI.  669 
Acute kidney injury was induced by i.p. injection of aristolochic acid (AA) (1x5mg/kg) in 10 670 
weeks old BALB/c male mice. Hematoxylin/eosin (HE), Masson’s trichrome blue (MTB) and 671 
α-smooth muscle actin (α-SMA) staining of mouse kidney sections (A) and MTB staining of 672 
liver sections (B) of untreated (controls), mice treated with N-Ac-γ-Glu-GSI, or after 673 
exposure to AA without or with N-Ac-γ-Glu-GSI treatment. Representative 674 
images/experimental groups are shown (40x). 675 
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Figure 4. Expression of Notch1 and cleaved Notch1 in the kidneys of mice treated with 676 
aristolochic acid and N-Ac-γ-Glu-GSI. 677 
(A) Frozen kidneys sections (7µm) of control and aristolochic acid (AA)-treated mice, 678 
without or with the N-Ac-γ-Glu-GSI, were exposed to either anti-Notch1 or anti-cleaved 679 
Notch1 antibodies, followed by the alkaline phosphatase-fast-red chromogen staining and 680 
hematoxylin counterstaining. Immunostaining is visualized as a red-brown precipitate. (B) 681 
Western blot analysis of cleaved Notch1 expression in kidney samples from control and AA-682 
treated mice, without or with the N-Ac-γ-Glu-GSI. Results of 3 representative 683 
mice/experimental group are shown. GAPDH was used as loading control and the intensities 684 
of the bands were quantified relative to GAPDH. 685 
 686 
Figure 5. Notch1 and inflammatory pathway-responsive genes in the kidneys of mice 687 
exposed to aristolochic acid and the N-Ac-γ-Glu-GSI. 688 
Acute kidney injury was induced by i.p. injection of aristolochic acid (AA) in 10 weeks old 689 
BALB/c male mice. At the end of the experiment (day 7 morning), the animals were 690 
sacrificed and mRNAs were extracted from the snap-frozen kidneys. The levels of expression 691 
of the mRNAs for (A) Notch1-responsive genes and (B) Notch1-inducible inflammatory 692 
markers were quantified by qRT-PCR and results were averaged for all animals in each 693 
experimental group. Results are presented as % of changes in the mRNA levels in the treated 694 
animals versus control animals + sem. (*p<0.05; **p<0.01; ***p<0.001). C. 695 
Immunohistochemistry staining of NFkB p65 on kidney sections of untreated (controls), 696 
control mice treated with N-Ac-γ-Glu-GSI, or after exposure to AA without or with N-Ac-γ-697 
Glu-GSI treatment. 698 
 699 
Figure 6. Modulation of genes of the renin-angiotensin system (RAS) in the kidneys of 700 
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mice administered aristolochic acid and treated with functionalized GSIs. 701 
After 7 days of treatment, with either (A) aristolochic acid (AA) alone or together with N-Ac-702 
γ-Glu-GSI or (B) AA alone or with amine-GSI, the animals were sacrificed and their kidneys 703 
extracted for the determination by qRT-PCR of the mRNA levels of genes of the components 704 
of the RAS. Results were averaged for all animals per experimental group and are presented 705 
as % of changes in the mRNA levels in the treated animals versus control animals + sem. 706 
(*p<0.05; **p< 0.01; ***p<0.001). 707 
 708 
Figure 7. Clinical parameters, Notch1-related pathways activation profiles and kidney 709 
histology of mice exposed to adriamycin and the amine-GSI. 710 
Glomerular injury was induced in 10 weeks old BALB/c male mice by i.p. injection of 711 
adriamycin (ADR). The amine-GSI metabolite was administered i.p., starting one day before 712 
injection of ADR (day -1) and then twice daily until day 6 evening. (A) Mice were monitored 713 
clinically daily, weighted and the level of proteinuria was semi-quantitatively assessed at day 714 
0, day 3 and day 6. Results were averaged for all mice per experimental group and means + sd 715 
are shown. (B) After 7 days of treatment, with either ADR alone or together with amine-GSI, 716 
the animals were sacrificed and mRNAs were extracted from the snap-frozen kidneys. The 717 
levels of expression of the mRNAs for the Notch1-inducible genes and genes of the renin-718 
angiotensin system (RAS) were quantified by qRT-PCR. Results were averaged for all 719 
animals per experimental group and are presented as % of changes in the mRNA levels in the 720 
treated animals versus the control animals + sem. (*p<0.05; **p<0.01; ***p<0.001). (C) 721 
Kidney sections histology with hematoxylin/eosin (HE) and Masson’s trichrome blue (MTB) 722 
stainings after ADR administration, alone or with amine-GSI. (D) Western blot analysis of 723 
cleaved Notch1expression in kidney samples from control and ADR-treated mice, without or 724 
with the amine-GSI. Results of 3 representative mice/experimental group are shown. GAPDH 725 
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was used as loading control and the intensities of the bands were quantified relative to 726 
GAPDH. 727 
 728 
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